logo
  

Peabody Projects Increase In Q3 Adj. EBITDA - Quick Facts

Peabody (BTU) reported an increase in preliminary third quarter adjusted EBITDA compared to prior year due to higher realized prices from robust seaborne coal demand and a non-cash gain on the sale of Millennium. In the third quarter, revenues and net loss attributable to stockholders was negatively impacted by approximately $238 million of unrealized mark-to-market losses primarily related to coal hedges contracted in the first half of 2021, the company noted.

The company expects third quarter revenue of $670 million to $690 million; net loss to stockholders of $40 million to $60 million; and adjusted EBITDA of $280 million to $290 million. Adjusted EBITDA for the prior year period was $95.4 million.

"Coal sales to customers were in excess of $900 million, the highest level in seven quarters. We remain optimistic about the future given strong coal pricing and global demand fundamentals," said Peabody CEO Jim Grech.

Shares of Peabody were up 1.7% in pre-market trade on Monday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively. The Federal Trade Commission or FTC has ordered Walmart, Amazon, Kroger and certain other large wholesalers and suppliers to provide information to help it study causes of supply chain disruptions. The agency has launched an inquiry to find the reasons for empty shelves and exorbitant prices. Along with Walmart, Amazon.com, and Kroger, the order has been sent to C&S Wholesale Grocers, Associated.. Covid vaccine maker Moderna Inc.'s Chief Executive Stéphane Bancel has predicted that existing COVID-19 vaccines will be much less effective against Omicron than earlier strains, according to the Financial Times.
Follow RTT